Close

Acorda Therapeutics (ACOR) Tops Q3 EPS Views; Reaffirms AMPYRA Sales Outlook

October 31, 2012 6:08 AM EDT Send to a Friend
Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of $0.38, $0.28 better than ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login